Tower Research Capital (TRC)’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-27,672
| Closed | -$261K | – | 5614 |
|
|
2020
Q3 | $261K | Buy |
27,672
+18,619
| +206% | +$177K | ﹤0.01% | 2310 |
|
|
2020
Q2 | $69K | Buy |
+9,053
| New | +$69.3K | ﹤0.01% | 2795 |
|
|
2020
Q1 | – | Sell |
-5,945
| Closed | -$72K | – | 4359 |
|
|
2019
Q4 | $72K | Sell |
5,945
-5,432
| -48% | -$59.4K | 0.01% | 1130 |
|
|
2019
Q3 | $131K | Sell |
11,377
-8,644
| -43% | -$91K | 0.01% | 1197 |
|
|
2019
Q2 | $200K | Buy |
+20,021
| New | +$216K | 0.01% | 852 |
|
|
2018
Q4 | – | Sell |
-8,685
| Closed | -$173K | – | 4621 |
|
|
2018
Q3 | $173K | Buy |
+8,685
| New | +$198K | 0.01% | 1051 |
|
|
2017
Q3 | – | Sell |
-106
| Closed | -$2K | – | 4304 |
|
|
2017
Q2 | $2K | Sell |
106
-1,994
| -95% | -$39.5K | ﹤0.01% | 2417 |
|
|
2017
Q1 | $47K | Sell |
2,100
-897
| -30% | -$21.5K | ﹤0.01% | 766 |
|
|
2016
Q4 | $104K | Buy |
2,997
+1,129
| +60% | +$33.7K | 0.01% | 953 |
|
|
2016
Q3 | $46K | Buy |
+1,868
| New | +$46.7K | ﹤0.01% | 1199 |
|
|
2015
Q4 | – | Sell |
-476
| Closed | -$19K | – | 5317 |
|
|
2015
Q3 | $19K | Sell |
476
-630
| -57% | -$39.1K | ﹤0.01% | 1788 |
|
|
2015
Q2 | $76K | Sell |
1,106
-3,608
| -77% | -$227K | 0.01% | 1058 |
|
|
2015
Q1 | $258K | Sell |
4,714
-526
| -10% | -$25.1K | 0.03% | 309 |
|
|
2014
Q4 | $223K | Buy |
5,240
+2,129
| +68% | +$76.9K | 0.02% | 277 |
|
|
2014
Q3 | $99K | Buy |
+3,111
| New | +$66.3K | 0.01% | 968 |
|
|
2014
Q2 | – | Sell |
-670
| Closed | -$13K | – | 4860 |
|
|
2014
Q1 | $13K | Sell |
670
-1,244
| -65% | -$26.4K | ﹤0.01% | 2375 |
|
|
2013
Q4 | $46K | Buy |
1,914
+1,469
| +330% | +$34.5K | 0.01% | 1468 |
|
|
2013
Q3 | $10K | Buy |
445
+23
| +5% | +$543 | ﹤0.01% | 3225 |
|
|
2013
Q2 | $9K | Buy |
+422
| New | +$9.3K | ﹤0.01% | 2489 |
|
Tower Research Capital (TRC)'s AMAG Position: Q4 2020 in Review
Tower Research Capital (TRC) sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 27,672 shares — an estimated $261K sold.
Tower Research Capital (TRC) first reported a position in AMAG in Q2 2013 and held it in 19 quarters. The position peaked at $261K in Q3 2020. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Tower Research Capital (TRC) reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 27,672 AMAG Pharmaceuticals shares in Q4 2020, an estimated $261K.
- Tower Research Capital (TRC) first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 19 quarters.
- Tower Research Capital (TRC)'s AMAG Pharmaceuticals position peaked at $261K in Q3 2020.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2020, filed 16 Feb 2021.